Media headlines about Esperion Therapeutics (NASDAQ:ESPR) have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research firm rates the sentiment of news coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Esperion Therapeutics earned a media sentiment score of 0.19 on Accern’s scale. Accern also assigned media coverage about the biopharmaceutical company an impact score of 46.0858743018377 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
Here are some of the news headlines that may have impacted Accern Sentiment Analysis’s rankings:
- Esperion Announces Inducement Grants Under NASDAQ Listing … – Nasdaq (nasdaq.com)
- Jefferies Group Weighs in on Esperion Therapeutics, Inc.’s Q3 2017 Earnings (NASDAQ:ESPR) (americanbankingnews.com)
- Investors watching summary on Esperion Therapeutics, Inc. (ESPR) – Wall Street Morning (wallstreetmorning.com)
- Esperion Therapeutics, Inc. (ESPR) Downgraded to Sell at Zacks Investment Research (americanbankingnews.com)
- Esperion Therapeutics (ESPR) Prices 3.1M Share Common Offering at $49/Sh (streetinsider.com)
Several research analysts have issued reports on ESPR shares. Zacks Investment Research lowered Esperion Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, May 1st. ValuEngine upgraded Esperion Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, June 2nd. Citigroup Inc. reiterated a “buy” rating on shares of Esperion Therapeutics in a research note on Thursday, June 22nd. Jefferies Group LLC started coverage on Esperion Therapeutics in a research note on Monday, July 10th. They set a “hold” rating and a $55.00 price objective for the company. Finally, Stifel Nicolaus reiterated a “buy” rating and set a $60.00 price objective (up from $45.00) on shares of Esperion Therapeutics in a research note on Monday, June 26th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and nine have given a buy rating to the company’s stock. Esperion Therapeutics has a consensus rating of “Hold” and a consensus price target of $42.51.
Shares of Esperion Therapeutics (NASDAQ ESPR) opened at 49.33 on Friday. The company’s market cap is $1.11 billion. The stock’s 50 day moving average price is $47.09 and its 200 day moving average price is $35.27. Esperion Therapeutics has a one year low of $9.40 and a one year high of $57.38.
Esperion Therapeutics (NASDAQ:ESPR) last posted its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($1.92) EPS for the quarter, missing analysts’ consensus estimates of ($1.67) by $0.25. During the same period in the prior year, the business earned ($0.62) earnings per share. Equities analysts predict that Esperion Therapeutics will post ($7.29) earnings per share for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: This news story was posted by Transcript Daily and is owned by of Transcript Daily. If you are accessing this news story on another site, it was copied illegally and republished in violation of United States & international copyright & trademark laws. The correct version of this news story can be viewed at https://transcriptdaily.com/2017/08/13/esperion-therapeutics-espr-given-coverage-optimism-rating-of-0-19.html.
About Esperion Therapeutics
Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.
Receive News & Ratings for Esperion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.